Impact of repurposed drugs on the symptomatic COVID-19 patients

dc.creatorHussain, Iqbal
dc.creatorHussain, Afzal
dc.creatorAlajmi, Mohamed F.
dc.creatorRehman, Md. Tabish
dc.creatorAmir, Samira
dc.date.accessioned2020-12-09T19:52:55Z
dc.date.available2020-12-09T19:52:55Z
dc.date.created2020
dc.description.abstractAn outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus capable of causing coronavirus disease 2019 (COVID-19), was declared as a global public health emergency on January 30, 2020, by the World Health Organization. In this devastating situation, precautionary measures, early diagnosis, and repurposed drugs appear to be timely and decisive factors by which to handle this problem until the discovery of an effective, dedicated vaccine or medicine is made. Currently, some researchers and clinicians have claimed evidence exists in favor of the use of some antimalarial drugs (chloroquine, hydroxychloroquine) antiviral drugs (remdesivir, favipiravir, lopinavir, ritonavir, umifenovir) vitamins, traditional Chinese medicines, and herbal medicines against SARS-CoV-2 infection. Based on the available literature, this review article sought to highlight the current understanding of the origin, transmission, diagnosis, precautionary measures, infection and drug action mechanisms, therapeutic role, and toxicities of targeted drugs for the prevention and cure of COVID‐19. This review may be useful for developing further strategies as a blueprint and understanding the mentioned drugs’ mechanismsto elucidate the possible target of action by which to successfully freeze the replication of the SARS-CoV-2 virus.spa
dc.format.extent63 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.jiph.2020.11.009spa
dc.identifier.issn1876-0341(spa
dc.identifier.otherhttps://doi.org/10.1016/j.jiph.2020.11.009spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/16422
dc.language.isoengspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.subjectCOVID-19spa
dc.subjectDiagnosisspa
dc.subjectPrecautionary measuresspa
dc.subjectChloroquinespa
dc.subjectHydroxychloroquinespa
dc.subjectRemdesivirspa
dc.subjectFavipiravirspa
dc.subjectLopinavirspa
dc.subjectRitonavirspa
dc.subjectUmifenovirspa
dc.subjectDrug toxicitiesspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleImpact of repurposed drugs on the symptomatic COVID-19 patientsspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: